Mr. Chubb, a founder of Matritech, has been Chairman since October 1993 and a director and Matritech's Chief Executive Officer since the Company's inception in 1987. Mr. Chubb was the Company's President until October 1993 and was also Treasurer of the Company until March 1992. From 1984 to 1986, Mr. Chubb served as President and Chief Executive Officer of T Cell Sciences, Inc., a publicly-traded biotechnology company. Prior to 1984, Mr. Chubb was President and Chief Executive Officer of Cytogen Company, also a publicly-traded biotechnology company. He currently serves as a director of Charles River Laboratories, a publicly-traded medical products company and Trustee of Mt. Auburn Hospital, Cambridge, MA.

Mr. Corbet has been Matritech's President, Chief Operating Officer and a director since October 1993, and joined the Company in April 1993 as Executive Vice President. Prior to joining Matritech and since 1991, Mr. Corbet had served as President and Chief Operating Officer of T Cell Diagnostics, Inc., a subsidiary of T Cell Sciences, Inc., which was a publicly-traded biotechnology company, and had served in various other executive and managerial offices there since 1985.

Dr. Domurad has been Matritech's Vice President, Clinical and Regulatory Affairs since January 2000. From October 1997 to December 1999 she was Matritech's Director of Clinical and Regulatory Affairs. From 1994 to 1997, she served as Director of Clinical Research of ErgoScience Development Corporation, a publicly-traded biopharmaceutical company. Prior to 1994, Dr. Domurad was Director of Operations of the Center for the Study of Nutrition Medicine at the Beth Israel Deaconess Medical Center, a Harvard Medical School facility.

Dr. Fagan has been Matritech's Vice President, Research and Development, since October 2004, and joined the Company in November 2003 as Senior Director of Product Development. Prior to joining Matritech, Dr. Fagan served from 1999 to November 2003 as Vice President, Research and Development, of Ischemia Technologies, an in-vitro diagnostics company. From 1989 to 1998, he served in a number of research positions at PB Diagnostics and Behring Diagnostics, both predecessor companies to Dade Behring, before serving as a senior research manager at Dade Behring, a publicly-traded diagnostics company.

Mr. Kolasinski, a veteran diagnostic and point-of-care product sales executive with more than 30 years of experience joined the Company as Vice President, Sales in March 2006. Mr. Kolasinski built and led the point-of-care sales team at Boehringer Mannheim, one of the world’s largest in vitro diagnostic (IVD) companies and now Roche Boehringer Mannheim Diagnostics. At Boehringer Mannheim he successfully marketed new IVD products directly to physicians, increasing both sales and market share. Before joining Matritech, Mr. Kolasinski was Vice President of Business Development of Inproteo, the Indiana Proteomics Consortium, which is owned by Eli Lilly, Indiana University and Purdue University. Previously he held a number of senior positions in sales and commercial operations in large diagnostic companies including Amersham Corporation/Life Sciences Division as Vice President and General Manager; Abbott Laboratories/Diagnostic Division, where he held a number of positions of increasing responsibility in worldwide sales and marketing; and at Baxter Laboratories, where he held several positions in sales and marketing management for its diagnostic products.

Mr. Quigley has been Matritech's Vice President, Sales and Marketing since July 2001. From December 2000 until April 2001, he was Director of Marketing for Argose, Inc., a medical diagnostic products company. From 1998 until May 2000, Mr. Quigley was the Vice President of Global Marketing for Bayer's Critical Care business unit. From January 1997 until 1998, Mr. Quigley was Director of U.S. Marketing at Chiron Diagnostics, a publicly traded biotech and diagnostics company that was acquired by Bayer. From 1994 until 1997, Mr. Quigley was Director of Marketing at Boehinger Mannheim, a privately held diagnostics company.

Ms. Randall has been Matritech’s Vice President, General Counsel, Chief Legal Officer and Secretary since December 2003. From 2001 to 2003, Ms. Randall served as Vice President and General Counsel of Robotic Vision Systems, Inc., a publicly traded technology company. From 1998 to 2000, she served as Vice President and General Counsel of Hadco Corporation, a publicly traded technology company. From 1980 to 1998, Ms. Randall was a partner at the Boston law firm of Hamilton, Dahmen and Randall.

Mr. Sandberg has served as a director of Matritech from April 1999 excluding a brief hiatus between June 2002 and September 2002 when Mr. Sandberg was reappointed to the Board of Directors to fill a vacancy created by the Board. Mr. Sandberg has been Matritech’s Chief Financial Officer, Vice President Finance and Treasurer since November 2002 and a member of the Board of Directors from September 2002 and previously from April 1999 to June 2002. Mr. Sandberg served as Secretary of Matritech from November 2002 to December 2003. Mr. Sandberg also serves as Chief Strategic Advisor and as a director of ML Holdings LLC, a laboratory services holding company in Toledo, Ohio. From 1997 to 2001, Mr. Sandberg served as Chairman of the Board of Lifecodes Corporation, a manufacturer of DNA test kits and a provider of DNA testing services, and served as Chief Financial Officer of Lifecodes Corporation from May 1997 to September 1998. From 1983 to 1997, Mr. Sandberg served in a variety of positions including Chairman, Chief Executive Officer and Chief Financial Officer at DIANON Systems, Inc., a publicly-traded oncology marketing and database company. Mr. Sandberg serves as a director of Ethan Allen Interiors, Inc., a publicly traded home decorating company.

Mr. Maier has served as president of Matritech GmbH, the Company’s subsidiary based in Germany, since 2000. Mr. Maier was Chief Executive Officer of ADL GmbH, a German distributor of medical diagnostic products, from 1996 to 2000, and was a country manager for Germany for Pharmacia Diagnostics, a manufacturer of in vitro diagnostic products, from 1989 to 1995.